Xencor

Xencor XNCR Stock

$33.26   -2.205234%
Add to favorites
Market Cap
$2.50B
LOW - HIGH [24H]
$33.12 - $34.27
VOLUME [24H]
$1.22M
P/E Ratio
0
Earnings per share
-$1.56
ISIN
US98401F1057
Price   Prediction

Xencor Price Chart

Sorry, that's all we've gotfor now...

Xencor (XNCR) stock price today is 33.26 USD on Tech Market Middle (-2.21% on the day). Updated .

Xencor XNCR Financial and Trading Overview

Xencor stock price 33.26 USD
Previous Close 34.01 USD
Open 33.41 USD
Bid 14.35 USD x 200
Ask 25.39 USD x 200
Day's Range 33.12 - 34.27 USD
52 Week Range 10.38 - 40.6 USD
Volume 1.22M USD
Avg. Volume 1.53M USD
Market Cap 2.5B USD
Beta (5Y Monthly) 0.773
PE Ratio (TTM) N/A
EPS (TTM) -1.56 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 43.83 USD

XNCR Valuation Measures

Enterprise Value 2.25B USD
Trailing P/E N/A
Forward P/E -8.810059
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 12.448352
Price/Book (mrq) 4.437033
Enterprise Value/Revenue 11.227
Enterprise Value/EBITDA -16.567

Trading Information

Xencor Stock Price History

Beta (5Y Monthly) 0.773
52-Week Change 114.30%
S&P500 52-Week Change 8.67%
52 Week High 40.6 USD
52 Week Low 10.38 USD
50-Day Moving Average 28.09 USD
200-Day Moving Average 18.56 USD

XNCR Share Statistics

Avg. Volume (3 month) 1.53M USD
Avg. Daily Volume (10-Days) 1.21M USD
Shares Outstanding 75.04M
Float 55.81M
Short Ratio 7.59
% Held by Insiders 1.19%
% Held by Institutions 118.34%
Shares Short 12.9M
Short % of Float 24.29%
Short % of Shares Outstanding 17.19%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -58.78%
Operating Margin (ttm) -72.66%
Gross Margin -42.49%
EBITDA Margin -67.76%

Management Effectiveness

Return on Assets (ttm) -11.10%
Return on Equity (ttm) -19.87%

Income Statement

Revenue (ttm) 200.49M USD
Revenue Per Share (ttm) 2.66 USD
Quarterly Revenue Growth (yoy) 454.90%
Gross Profit (ttm) -85201000 USD
EBITDA -135872000 USD
Net Income Avi to Common (ttm) -117862000 USD
Diluted EPS (ttm) -1.56
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 405.08M USD
Total Cash Per Share (mrq) 5.4 USD
Total Debt (mrq) 160.23M USD
Total Debt/Equity (mrq) 28.59 USD
Current Ratio (mrq) 6.538
Book Value Per Share (mrq) 7.496

Cash Flow Statement

Operating Cash Flow (ttm) -172355008 USD
Levered Free Cash Flow (ttm) -96220752 USD

Profile of Xencor

Country United States
State CA
City Pasadena
Address 465 North Halstead Street
ZIP 91107
Phone 626 305 5900
Website https://www.xencor.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 260

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Q&A For Xencor Stock

What is a current XNCR stock price?

Xencor XNCR stock price today per share is 33.26 USD.

How to purchase Xencor stock?

You can buy XNCR shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Xencor?

The stock symbol or ticker of Xencor is XNCR.

Which industry does the Xencor company belong to?

The Xencor industry is Biotechnology.

How many shares does Xencor have in circulation?

The max supply of Xencor shares is 75.04M.

What is Xencor Price to Earnings Ratio (PE Ratio)?

Xencor PE Ratio is now.

What was Xencor earnings per share over the trailing 12 months (TTM)?

Xencor EPS is -1.56 USD over the trailing 12 months.

Which sector does the Xencor company belong to?

The Xencor sector is Healthcare.

Xencor XNCR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Global Market Composite NQGM US 1743.91 USD —
-3.66
— — 1738.23 USD — 1808.43 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7414.87 USD —
-1.68
— — 7398.95 USD — 7631.86 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 2801.87 USD —
-2.68
— — 2797.1 USD — 2892.69 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3419.87 USD —
-3.87
— — 3408.51 USD — 3548.76 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech Composite Total Return XCMP US 27958.09 USD —
-5.28
— — 27828.65 USD — 29466.09 USD — — — —
$2.07T
Total marketcap
$93.39B
Total volume
BTC 57.78%   •   ETH 9.83%
Dominance
Select currency